Doer Biologics has dosed the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia (SHTG).

A new neuroimaging marker, peak-width of skeletonized mean diffusivity (PSMD), correlates with general cognition and may identify individuals at risk of dementia.

A randomized controlled trial is underway to assess the impact of a Patient Health Engagement (PHE) model on rehabilitation participation in patients with Acute Myocardial Infarction (AMI) post-Percutaneous Coronary Intervention (PCI).

Allogene Therapeutics is conducting the ALPHA3 trial to evaluate early intervention with CAR-T therapy in LBCL patients identified as high-risk for relapse.

HPK1 inhibition is emerging as a strategy to enhance T-cell functionality and improve immunotherapy efficacy in solid tumors, with several inhibitors in early-phase trials.

Johnson & Johnson has submitted a request to the FDA for approval of a subcutaneous injection-based treatment option for Tremfya in adults with ulcerative colitis.

A Phase II trial of xalnesiran plus immunomodulators showed significant hepatitis B surface antigen (HBsAg) loss in patients with chronic HBV infection.

Trastuzumab deruxtecan (T-DXd) is now approved for HER2-positive solid tumors after prior systemic therapy, impacting treatment strategies for NSCLC.

Gamma secretase inhibition (GSI) alters gene expression in multiple myeloma (MM) bone marrow cells, affecting 567 genes across 20 cell types, indicating broad impacts beyond tumor killing.

Tovorafenib (Ojemda) demonstrates durable responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma during drug holidays in the FIREFLY-1 trial.

A retrospective study of 9,146 patients revealed no significant difference in overall survival (OS) among palbociclib, ribociclib, and abemaciclib when combined with aromatase inhibitors as first-line treatment for HR+/HER2- metastatic breast cancer.

Tovorafenib (Ojemda) shows promise in improving health-related quality of life (HRQOL) in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

Vir Biotechnology's Phase 2 SOLSTICE trial demonstrated a 100% virologic response in chronic hepatitis delta (CHD) patients using tobevibart and elebsiran combination therapy.

GSK's linerixibat met the primary endpoint in the GLISTEN phase III trial, demonstrating a statistically significant reduction in itch for PBC patients.

SpyGlass Pharma has finished enrolling patients in its Phase I/II clinical trial evaluating its drug delivery platform for glaucoma and ocular hypertension.

Icotrokinra, an oral peptide targeting the IL-23 receptor, met primary endpoints in two Phase 3 trials for moderate-to-severe plaque psoriasis.

Puma Biotechnology has commenced the ALISCA™-Breast1 Phase II trial to evaluate alisertib combined with endocrine therapy for HR+/HER2- metastatic breast cancer.

Semaglutide significantly improved liver fibrosis and MASH resolution compared to placebo in a Phase III trial, marking a potential breakthrough in treatment.

INS018_055, an AI-discovered drug developed by Insilico Medicine, has advanced to Phase 2 clinical trials for Idiopathic Pulmonary Fibrosis (IPF).

Incyte will present new data from its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.